IRWD
Income statement / Annual
Last year (2023), Ironwood Pharmaceuticals, Inc.'s total revenue was $442.74 M,
an increase of 7.83% from the previous year.
In 2023, Ironwood Pharmaceuticals, Inc.'s net income was -$1.00 B.
See Ironwood Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$442.74 M
|
$410.60 M
|
$413.75 M
|
$389.52 M
|
$428.41 M
|
$346.64 M
|
$298.28 M
|
$273.96 M
|
$149.56 M
|
$76.44 M
|
| Cost of Revenue |
$1.58 M |
$1.42 M |
$1.52 M |
$3.14 M |
$23.88 M |
$32.75 M |
$19.41 M |
$1.87 M |
$12,000.00 |
$25.58 M |
| Gross Profit |
$441.16 M |
$409.18 M |
$412.23 M |
$386.39 M |
$404.54 M |
$313.89 M |
$278.87 M |
$272.09 M |
$149.54 M |
$50.85 M |
| Gross Profit Ratio |
1 |
1 |
1 |
0.99 |
0.94 |
0.91 |
0.93 |
0.99 |
1 |
0.67 |
| Research and Development
Expenses |
$116.09 M
|
$44.27 M
|
$70.41 M
|
$88.06 M
|
$115.04 M
|
$166.50 M
|
$148.23 M
|
$139.49 M
|
$108.75 M
|
$101.89 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$241.29 M
|
$233.12 M
|
$173.28 M
|
$125.25 M
|
$118.33 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$158.31 M
|
$115.99 M
|
$111.13 M
|
$140.00 M
|
$172.45 M
|
$241.29 M
|
$233.12 M
|
$173.28 M
|
$125.25 M
|
$118.33 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$24,000.00 |
$514,000.00 |
$8.11 M |
$6.21 M |
$981,000.00 |
$17.64 M |
$661,000.00 |
| Operating Expenses |
$232.12 M |
$160.26 M |
$181.54 M |
$228.07 M |
$287.49 M |
$415.91 M |
$387.57 M |
$313.75 M |
$233.99 M |
$220.22 M |
| Cost And Expenses |
$233.70 M |
$160.26 M |
$181.54 M |
$231.20 M |
$311.37 M |
$448.66 M |
$406.97 M |
$315.62 M |
$234.01 M |
$245.81 M |
| Interest Income |
$18.97 M |
$9.50 M |
$726,000.00 |
$1.50 M |
$2.86 M |
$2.99 M |
$2.11 M |
$1.17 M |
$443,000.00 |
$257,000.00 |
| Interest Expense |
$21.63 M |
$7.60 M |
$31.15 M |
$29.48 M |
$36.60 M |
$34.73 M |
$34.26 M |
$37.98 M |
$30.65 M |
$21.17 M |
| Depreciation &
Amortization |
$1.58 M
|
$1.42 M
|
$1.52 M
|
$3.56 M
|
$5.58 M
|
$11.97 M
|
$14.62 M
|
$11.26 M
|
$11.63 M
|
$12.33 M
|
| EBITDA |
-$924.86 M
|
$261.44 M
|
$233.33 M
|
$141.90 M
|
$101.13 M
|
-$144.45 M
|
-$33.12 M
|
-$31.30 M
|
-$99.94 M
|
-$156.12 M
|
| EBITDA Ratio |
-2.09 |
0.63 |
0.56 |
0.41 |
0.28 |
-0.27 |
-0.34 |
-0.15 |
-0.56 |
-2.22 |
| Operating Income Ratio
|
0.47
|
0.61
|
0.56
|
0.37
|
0.28
|
-0.69
|
-0.26
|
-0.19
|
-0.68
|
-2.22
|
| Total Other
Income/Expenses Net |
-$1.16 B
|
$2.09 M
|
-$31.60 M
|
-$34.08 M
|
-$61.18 M
|
-$43.48 M
|
-$71.16 M
|
-$29.84 M
|
-$40.58 M
|
-$20.25 M
|
| Income Before Tax |
-$948.07 M |
$252.42 M |
$200.66 M |
$108.86 M |
$58.94 M |
-$282.37 M |
-$116.94 M |
-$81.71 M |
-$142.67 M |
-$189.62 M |
| Income Before Tax Ratio
|
-2.14
|
0.61
|
0.48
|
0.28
|
0.14
|
-0.81
|
-0.39
|
-0.3
|
-0.95
|
-2.48
|
| Income Tax Expense |
$83.49 M |
$77.36 M |
-$327.79 M |
$2.69 M |
$74.26 M |
-$5.75 M |
$34.26 M |
$37.98 M |
$19.02 M |
$8.58 M |
| Net Income |
-$1.00 B |
$175.07 M |
$528.45 M |
$106.18 M |
-$15.31 M |
-$282.37 M |
-$116.94 M |
-$81.71 M |
-$142.67 M |
-$189.62 M |
| Net Income Ratio |
-2.26 |
0.43 |
1.28 |
0.27 |
-0.04 |
-0.81 |
-0.39 |
-0.3 |
-0.95 |
-2.48 |
| EPS |
-6.45 |
1.13 |
3.26 |
0.67 |
-0.0982 |
-1.85 |
-0.79 |
-0.56 |
-1 |
-1.39 |
| EPS Diluted |
-6.45 |
0.94 |
3.21 |
0.66 |
-0.0982 |
-1.85 |
-0.78 |
-0.56 |
-1 |
-1.39 |
| Weighted Average Shares
Out |
$155.44 M
|
$154.37 M
|
$162.25 M
|
$159.43 M
|
$156.02 M
|
$152.63 M
|
$148.42 M
|
$144.93 M
|
$142.16 M
|
$136.81 M
|
| Weighted Average Shares
Out Diluted |
$155.44 M
|
$186.31 M
|
$164.42 M
|
$160.66 M
|
$156.02 M
|
$152.63 M
|
$148.99 M
|
$145.91 M
|
$142.16 M
|
$136.81 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
